India’s diagnostics queen

Being a woman entrepreneur in India isn’t a rosy journey. Running a business owned by the family may sound too cool and easy. But it is not so

ms-ameera-shah-md-ceo-metropolis-healthcare

Ms Ameera Shah, MD & CEO, Metropolis Healthcare

Despite the hard struggles in a male-dominated society, women have fought bravely and stood their grounds against all odds. Ms Ameera Shah, the MD and promoter of Mumbai-based Metropolis Healthcare, isn't an exception either.

Though she took over her father's business, the journey wasn't a cake walk. She was often mistaken for a secretary, and had to overcome gender discrimination and belittling from junior male colleagues.

In her exclusive interview to BioSpectrum, she shares her insights on Indian diagnostics scene, the company's next market expansion plans, and ultimately her own entrepreneurial struggles and immeasurable efforts in building her own diagnostics kingdom. Excerpts:

Q: What trends are shaping up the Indian diagnostics space?

Ameera Shah: The most important trend today that we observe is the heightened awareness of the new age customer. They take their health in their own hands, take preventive measures and want to lead a healthy lifestyle.

For today's customer, health is about wellness rather than the absence of illness which is an extremely wonderful trend.

 

Previous 1 3 4 5 6 7 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

BusinessWire India.com - Healthcare & biotechnology

Bwi-logo

Philip Morris International Announces €300 Million Investment in Smoke-Free

Wednesday, 22 Mar 2017   |   Philip Morris International

Business Wire India Converting existing cigarette factory in Greece into a production facility for

Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter® and Connectivity

Tuesday, 21 Mar 2017   |   Masimo

Business Wire India Masimo (NASDAQ: MASI) announced the CE marking of noninvasive blood pressure (NIBP)

Boehringer Ingelheim Phase III study now enrolling patients with progressive

Monday, 20 Mar 2017   |   Boehringer Ingelheim

Business Wire India For the first time, patients with different fibrosing lung diseases will be included

BusinessWire India.com - Pharmaceutical

Bwi-logo

Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter® and Connectivity

Tuesday, 21 Mar 2017   |   Masimo

Business Wire India Masimo (NASDAQ: MASI) announced the CE marking of noninvasive blood pressure (NIBP)

Boehringer Ingelheim Phase III study now enrolling patients with progressive

Monday, 20 Mar 2017   |   Boehringer Ingelheim

Business Wire India For the first time, patients with different fibrosing lung diseases will be included

Uninterrupted Pradaxa® Showed Less Major Bleeding than Warfarin in Atrial

Monday, 20 Mar 2017   |   Boehringer Ingelheim

Business Wire India In the RE-CIRCUIT® trial, there were less major bleeding and fewer serious adverse

BusinessWire India.com - Medical Devices

Bwi-logo

Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter® and Connectivity

Tuesday, 21 Mar 2017   |   Masimo

Business Wire India Masimo (NASDAQ: MASI) announced the CE marking of noninvasive blood pressure (NIBP)

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X